Home > Press > Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASHAbstract:Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in AROHSD1001, a Phase 1/2 clinical study of ARO-HSD, the companys investigational RNA interference...
Comprehensive review of heterogeneously integrated 2D materials
Mar 06, 2020 (Nanowerk News) In a paper published in NANO ("Heterogeneous Integration of 2D Materials: Recent Advances in Fabrication and Functional Device Applications"), a group of researchers from Sungkyunkwan University, South Korea provide a comprehensive review of heterogeneously integrated two dimensional (2D) materials from an extensive library of atomic...